XML 114 R73.htm IDEA: XBRL DOCUMENT
v3.20.2

Accrued Expenses (Tables) (Brooklyn ImmunoTherapeutics, LLC) | 9 Months Ended | 12 Months Ended
--- | --- | ---
Sep. 30, 2020 | Dec. 31, 2019
Brooklyn Immunotherapeutics, LLC [Member] |  |
Schedule of Accrued Expenses | Accrued expenses consist of the following:
|  | September 30, |  |  | December 31, |
|  | 2020 |  |  | 2019 |
Compensation payable |  | $ | 218,764 |  |  | $ | 540,513 |
Accrued general and administrative expenses |  |  | 182,625 |  |  |  | 94,265 |
Accrued research and development expenses |  |  | 149,258 |  |  |  | 695,551 |
Accrued interest |  |  | 135,140 |  |  |  | 90,512 |
Loss on legal settlement |  |  | - |  |  |  | 100,000 |
Total accrued expenses |  | $ | 685,787 |  |  | $ | 1,520,841 |
| Accrued expenses consist of the following:
|  | December 31, |
|  | 2019 |  |  | 2018 |
Compensation payable |  | $ | 540,513 |  |  | $ | 214,327 |
Deferred rent payable |  |  | - |  |  |  | 6,169 |
Accrued general and administrative expenses |  |  | 94,265 |  |  |  | 62,743 |
Accrued research and development expenses |  |  | 695,551 |  |  |  | 1,380,440 |
Accrued interest |  |  | 90,512 |  |  |  | 33,114 |
Loss on legal settlement |  |  | 100,000 |  |  |  | - |
Total accrued expenses |  | $ | 1,520,841 |  |  | $ | 1,696,793 |

X
- Definition Tabular disclosure of the components of accrued liabilities. + References No definition available. + Details
Name: | us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=NTN_BrooklynImmunotherpeuticsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |